Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women.
about
Longitudinal change in clinical fracture incidence after initiation of bisphosphonatesThe complex relation between bisphosphonate adherence and fracture reduction.Once-monthly risedronate for postmenopausal osteoporosisThe economics of improving medication adherence in osteoporosis: validation and application of a simulation model.Risedronate's Role in Reducing Hip Fracture in Postmenopausal Women with Established Osteoporosis.Methods to examine the impact of compliance to osteoporosis pharmacotherapy on fracture risk: systematic review and recommendationsDiagnosis and management of osteoporosis in the older seniorAdherence to monthly and weekly oral bisphosphonates in women with osteoporosisCost-effectiveness of enhancing adherence with oral bisphosphonates treatment in osteoporotic women: an empirical approach based on healthcare utilisation databases.Hypercalcaemia and hypocalcaemia: finding the balance.Overcoming problems with adherence to osteoporosis medication.Non-adherence with bisphosphonates among patients with osteoporosis: impact on fracture risk and healthcare cost.Persistence with denosumab and zoledronic acid among older women: a population-based cohort study.Longitudinal change in hip fracture incidence after starting risedronate or raloxifene: an observational study.Research and Education.Evaluation of a program of integrated care to reduce recurrent osteoporotic fractures.Quality of life and health status with zoledronic acid and generic alendronate--a secondary analysis of the Rapid Onset and Sustained Efficacy (ROSE) study in postmenopausal women with low bone mass.Effectiveness of oral bisphosphonates for primary prevention of osteoporotic fractures: evidence from the AIFA-BEST observational study.
P2860
Q33819111-CF94628C-2E1D-4396-8B84-96EDDFCD883FQ34086612-60D2AEAB-6461-4804-9826-53D37CFB29DDQ34272000-F236A3CB-03FB-425D-8FF8-AC7AD4A1D06BQ35198519-44CBCF02-8402-4D9A-881B-C728561CCECCQ35678676-B316FDB7-DE18-489E-9474-A0CE56F845BFQ35693057-6BAA1160-EA1A-49B8-88C3-28E65B9C09FDQ37199923-B0DEBB19-274F-40AF-AC5A-B2D55399BB7CQ37457324-FC331B04-EA51-4617-B491-C28329D3125AQ37684745-1990C21D-0406-41CC-8053-D4C886E257CAQ37736066-D316D2A0-F5E7-4EA8-9E3A-D6581BE2E1F1Q37820680-42FC5B17-7123-4C15-B324-B9BCA6951400Q38788967-CF0BB811-2395-451A-8927-21796AF17295Q39344669-1FA99A16-DBF9-4591-81D1-91C073C54724Q44381104-53E49540-73CB-4CD4-9E1E-9930BCD94B2CQ45762885-DFB3EC80-9F1D-421E-9892-C36E085A7B26Q46356238-36A9ECF8-5A56-40CF-8BB5-B9519C62E29CQ48545123-DFE90F22-7F81-4ACF-933D-38E0187DAE69Q51821379-639687B9-C0AB-4C3D-84F1-13414D2174C5
P2860
Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Impact of noncompliance with a ...... ic fractures in elderly women.
@ast
Impact of noncompliance with a ...... ic fractures in elderly women.
@en
type
label
Impact of noncompliance with a ...... ic fractures in elderly women.
@ast
Impact of noncompliance with a ...... ic fractures in elderly women.
@en
prefLabel
Impact of noncompliance with a ...... ic fractures in elderly women.
@ast
Impact of noncompliance with a ...... ic fractures in elderly women.
@en
P2093
P2860
P1476
Impact of noncompliance with a ...... ic fractures in elderly women.
@en
P2093
Alice Dragomir
Julie Blouin
Julio Cesar Fernandes
Louis-Georges Ste-Marie
Sylvie Perreault
Yola Moride
P2860
P304
P356
10.1111/J.1365-2125.2008.03178.X
P407
P577
2008-05-06T00:00:00Z